Výsledky vyhledávání - "Melinda J. Reese"

Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment fromin vitrostudies and a clinical investigation with midazolam

Autor: Susan L Ford, Gary D Bowers, Lindsey O. Webster, Elizabeth P Gould, Joseph W. Polli, Melinda J. Reese, Joan E. Humphreys

Publikováno v: Xenobiotica. 46:445-456

1. Cabotegravir (CAB; GSK1265744) is a potent HIV integrase inhibitor in clinical development as an oral lead-in tablet and long-acting injectable for the treatment and prevention of HIV infection. 2. This work investigated if CAB was a substrate for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ee029c6cb38b7a6d4adef529a07b55e
https://doi.org/10.3109/00498254.2015.1081993

Zobrazit plný text záznamu

Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase™

Autor: Christine M. Hunt, Jeffrey I. Ambroso, Katarina Ilic, Ayako Suzuki, J. Gregory Falls, H. Roger Brown, Nancy A. Yuen, Richard T. Miller, Melinda J. Reese

Publikováno v: Regulatory Toxicology and Pharmacology. 72:481-490

Polypharmacy is common, and may modify mechanisms of drug-induced liver injury. We examined the effect of these drug-drug interactions on liver safety reports of four drugs highly associated with hepatotoxicity. In the WHO VigiBase™, liver event re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ec503a4208838d275d157dd94b6e69b
https://doi.org/10.1016/j.yrtph.2015.05.004

Zobrazit plný text záznamu

Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans

Autor: Phuong Huynh, David S. Wagner, Lee Moss, William Spreen, Yu Lou, Gary D Bowers, Susan L. Ford, Amanda G. Culp, Rennan Pan, Melinda J. Reese, Glenn Tabolt, David A. Margolis, Stephen C. Piscitelli, Elizabeth Gould

Publikováno v: Xenobiotica. 46:147-162

1. Cabotegravir [(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide] is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24bf26e1cbb6454fe0e0bcb222d0ef45
https://doi.org/10.3109/00498254.2015.1060372

Zobrazit plný text záznamu

In Vitro Investigations into the Roles of Drug Transporters and Metabolizing Enzymes in the Disposition and Drug Interactions of Dolutegravir, a HIV Integrase Inhibitor

Autor: Paul M. Savina, Joseph W. Polli, Eri Kanaoka, Grant T. Generaux, James D. Clarke, Kelly A. Harmon, Helen Tracey, Melinda J. Reese, Joan E. Humphreys, Lindsey O. Webster

Publikováno v: Drug Metabolism and Disposition. 41:353-361

Dolutegravir (DTG; S/GSK1349572) is a potent HIV-1 integrase inhibitor with a distinct resistance profile and a once-daily dose regimen that does not require pharmacokinetic boosting. This work investigated the in vitro drug transport and metabolism

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::993f8bf7610b57cb92f53b9a937dadea
https://doi.org/10.1124/dmd.112.048918

Zobrazit plný text záznamu

Preclinical Strategy to Reduce Clinical Hepatotoxicity Using in Vitro Bioactivation Data for >200 Compounds

Autor: Jackie C. Bloomer, Melinda J. Reese, Stephen E. Clarke, Ian A. Baines, Cerys A. Lovatt, Andrew W Harrell, Jeffrey L. Ambroso, Liangfu Chen, Harma Ellens, Eric Yang, Melanie Z. Sakatis, Andrew Ayrton, Maxine A. Taylor

Publikováno v: Chemical Research in Toxicology. 25:2067-2082

Drug-induced liver injury is the most common cause of market withdrawal of pharmaceuticals, and thus, there is considerable need for better prediction models for DILI early in drug discovery. We present a study involving 223 marketed drugs (51% assoc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92c08214c430cf0bef6e6d94714880e5
https://doi.org/10.1021/tx300075j

Zobrazit plný text záznamu

Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies

Autor: Wenli Tao, J. Sigafoos, Robert L. Dobbins, Anita Kapur, Stephen Castellino, David S. Wagner, Joan E. Humphreys, Joseph W. Polli, Melinda J. Reese, Elizabeth K. Hussey, Gary D Bowers, Amanda G. Culp, Robin L. O'Connor Semmes

Publikováno v: Drug Metabolism and Disposition. 40:2090-2101

Remogliflozin etabonate is the ester prodrug of remogliflozin, a selective sodium-dependent glucose cotransporter-2 inhibitor. This work investigated the absorption, metabolism, and excretion of [(14)C]remogliflozin etabonate in humans, as well as th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e117e38342441abf69a32eb67645b2a1
https://doi.org/10.1124/dmd.112.047258

Zobrazit plný text záznamu

An integrated reactive metabolite evaluation approach to assess and reduce safety risk during drug discovery and development

Autor: Stephen E. Clarke, Melinda J. Reese, Ian A. Baines, Andrew W Harrell, Liangfu Chen, Melanie Z. Sakatis, Andy Ayrton, Lei Zhu, Jeffrey L. Ambroso, Eric Yang, Maxine A. Taylor

Publikováno v: Chemico-Biological Interactions. 192:60-64

Metabolic bioactivation is widely considered an undesirable event and a likely prerequisite step in the expression of drug-induced hepatotoxicity and hypersensitivity. Reducing bioactivation risk early in drug discovery, therefore, may help reduce co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56710f9cc9a18734baa5bdb21f1ed538
https://doi.org/10.1016/j.cbi.2010.10.005

Zobrazit plný text záznamu

An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction

Autor: Robert M. Wurm, Keith T. Muir, Lisa A St. John-Williams, Donavon J. McConn, Melinda J. Reese, Grant T. Generaux

Publikováno v: Drug Metabolism and Disposition. 36:1198-1201

There are documented clinical drug-drug interactions between bupropion and the CYP2D6-metabolized drug desipramine resulting in marked (5-fold) increases in desipramine exposure. This finding was unexpected as CYP2D6 does not play a significant role

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::817554c2d0e3b6e994ae64807c3eda5e
https://doi.org/10.1124/dmd.107.020198

Zobrazit plný text záznamu

Corrigendum to 'Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBaseTM' [Regul. Toxicol. Pharmacol. (2015) 481–490]

Autor: Ayako Suzuki, Melinda J. Reese, Christine M. Hunt, Nancy A. Yuen, Jeffrey I. Ambroso, Katarina Ilic, Richard T. Miller, J. Gregory Falls, H. Roger Brown

We identified the following errors in our paper, and apologize for any inconvenience: the legend below Fig. 2 describes Fig. 3 the legend below Fig. 3 describes Fig. 2 the foot note to Table 1 should refer to Supplemental Table 1 (rather than 2) on t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ff0556d3fbbeb59bd6ee1e465115316
https://europepmc.org/articles/PMC4662257/

Zobrazit plný text záznamu

The metabolic activation of abacavir by human liver cytosol and expressed human alcohol dehydrogenase isozymes

Autor: Melinda J. Reese, Linda M. Thurmond, John S Walsh

Publikováno v: Chemico-Biological Interactions. 142:135-154

Abacavir (ZIAGEN) is a reverse transcriptase inhibitor marketed for the treatment of HIV-1 infection. A small percentage of patients experience a hypersensitivity reaction indicating immune system involvement and bioactivation. A major route of metab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b1609eb140399bfc5283a740dfabbe
https://doi.org/10.1016/s0009-2797(02)00059-5

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání